膦酸二异丁基酯 | 13529-77-6

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 中文名称: 膦酸二异丁基酯
• 英文名称: phosphonic acid diisobutyl ester
• 英文别名: phosphorous acid diisobutyl ester；di-i-butyl phosphite；diisobutyl phosphite；bis(2-methylpropyl) hydrogen phosphite
• CAS: 13529-77-6
• 化学式: C₈H₁₉O₃P
• mdl: MFCD09038516
• 分子量: 194.211
• InChiKey: DVQJZMHWNRXGSM-UHFFFAOYSA-N

物化性质

• 沸点：
  235-236 °C
• 密度：
  0.9257 g/cm3(Temp: 0 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  膦酸二异丁基酯 在 sodium hydroxide 作用下， 生成 双(2-甲基丙基)磷酸氢盐
  参考文献：
  名称：

  Grosse-Ruyken,H.; Uhlig,K., Journal fur praktische Chemie (Leipzig 1954), 1962, vol. 18, p. 287 - 291

  摘要：

  DOI：
• 作为产物：
  描述：

  异丁醇 在 三氯化磷 作用下， 生成 膦酸二异丁基酯
  参考文献：
  名称：

  Grosse-Ruyken,H.; Uhlig,K., Journal fur praktische Chemie (Leipzig 1954), 1962, vol. 18, p. 287 - 291

  摘要：

  DOI：

文献信息

• Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity
  申请人：Winchell S. Harry

  公开号：US20050112066A1

  公开（公告）日：2005-05-26

  Cyclic polyaza chelators that possess high affinity and specificity for first transition series metal cations exhibit an unanticipated improvement in biological activity when administered as complexes with cations of the alkaline earth metals, Ca(II) and Mg(II), most notably Ca(II). By virtue of this improvement, these complexes are particularly effective in the treatment of pathological conditions, including ischemia and ischemia-reperfusion injury.

  具有高亲和力和特异性的环状多氮螯合剂，当与碱土金属阳离子的络合物一起给药时，表现出生物活性的意外改善，其中以Ca(II)和Mg(II)的络合物最为显著，尤其是Ca(II)。由于这种改善，这些络合物在治疗病理条件，包括缺血和缺血再灌注损伤方面特别有效。
• Guanidinoalkyl-1,1-bisphosphonic acid derivatives, process for their
  申请人：Hoechst Aktiengesellschaft

  公开号：US05294608A1

  公开（公告）日：1994-03-15

  The invention describes tautomeric compounds of the formula Ia, Ib or Ic ##STR1## and/or their physiologically tolerable salts, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are a hydrogen atom, substituted (C.sub.1 -C.sub.7)-alkyl, (C.sub.3 -C.sub.10)-cycloalkyl, substituted phenyl or (C.sub.1 -C.sub.4)-alkylphenyl, R.sup.2 is substituted phosphoric acid, R.sup.2 and R.sup.3, R.sup.2 and R.sup.5 or R.sup.4 and R.sup.5 form a monocyclic 5- to 7-membered saturated or unsaturated heterocyclic ring which is mono- or polysubstituted, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are a hydrogen atom or (C.sub.1 -C.sub.5)-alkyl, X is a hydrogen atom, hydroxyl or halogen, l and n are an integer from 0 to 7, m is an integer from 0 to 2, and the sum of the numbers l, m and n is less than or equal to 10, a process for the preparation of the compounds of the formula Ia, Ib or Ic, pharmaceuticals and their use for the prophylaxis or treatment of osteoporosis.

  该发明描述了公式Ia、Ib或Ic的互变异构化合物及/或其生理耐受盐，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7是氢原子，取代的（C.sub.1 -C.sub.7）-烷基，（C.sub.3 -C.sub.10）-环烷基，取代的苯基或（C.sub.1 -C.sub.4）-烷基苯基，R.sup.2是取代的磷酸，R.sup.2和R.sup.3，R.sup.2和R.sup.5或R.sup.4和R.sup.5形成单环5-至7-成员饱和或不饱和杂环环，该环是单取代或多取代的，R.sup.8、R.sup.9、R.sup.10和R.sup.11是氢原子或（C.sub.1 -C.sub.5）-烷基，X是氢原子、羟基或卤素，l和n是0至7之间的整数，m是0至2之间的整数，l、m和n的总和小于或等于10，一种制备公式Ia、Ib或Ic化合物的方法，以及用于预防或治疗骨质疏松症的药物及其使用。
• Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
  申请人：CONCAT, LTD. a California Limited Partnership

  公开号：US20040006055A1

  公开（公告）日：2004-01-08

  Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.

  表现出对第一过渡系列元素具有螯合亲和力和选择性的化合物被用于治疗患有缺血、持续性癫痫和创伤等疾病的患者，以提供神经保护、心脏保护或两者兼而有之。这些化合物在被给药时会与可螯合的铁和铜阳离子形成络合物，从而减轻这些阳离子催化哈伯-魏斯反应的能力，这些反应会产生导致组织损伤的有毒羟自由基。这些化合物还会与可螯合的锌阳离子形成络合物，从而抑制与过多可螯合锌相关的细胞毒性。
• [EN] METHOD OF MAKING HYDROXYMETHYLPHOSPHONATE, POLYURETHANE FOAM-FORMING COMPOSITIONS, POLYURETHANE FOAM AND ARTICLES MADE THEREFROM<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PHOSPHONATE D'HYDROXYMÉTHYLE, COMPOSITIONS FORMANT UNE MOUSSE DE POLYURÉTHANE, MOUSSE DE POLYURÉTHANE ET ARTICLES FAITS DE CETTE DERNIÈRE
  申请人：ICL IP AMERICA INC

  公开号：WO2014062313A1

  公开（公告）日：2014-04-24

  There is provided herein a method of making hydroxymethylphosphonate comprising reacting paraformaldehyde, at least one dialkyl phosphite and at least one trialkyl phosphite, in the presence of at least one amine catalyst.

  本文提供了一种制备羟甲基膦酸酯的方法，包括在至少一种胺催化剂的存在下，反应多聚甲醛、至少一种二烷基膦酸酯和至少一种三烷基膦酸酯。
• Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
  申请人：——

  公开号：US20010041170A1

  公开（公告）日：2001-11-15

  This invention involves the use of a class of compounds with chelation affinity and selectivity for first transition series elements. Application or administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease of the bioavailability and/or chemical action of first transition series elements. These characteristics make such compounds useful in cosmetics and personal care products to decrease odor arising from microbial growth on body surfaces and in body cavities, decrease microbial growth on teeth, plaque, and gums that cause tooth decay and gum disease, inhibition of oxidative damage to the skin, inhibition of enzymatic action of metalloenzymes dependent on first transition series elements, and inhibition of reperfusion injury.

  这项发明涉及使用一类对第一过渡系列元素具有螯合亲和力和选择性的化合物。应用或给予自由或结合化合物，或自由或结合化合物的生理盐，可导致第一过渡系列元素的生物利用度和/或化学作用降低。这些特性使得这些化合物在化妆品和个人护理产品中非常有用，可减少身体表面和身体腔内微生物生长引起的气味，减少导致牙齿蛀牙和牙龈疾病的牙菌斑和牙龈微生物生长，抑制皮肤氧化损伤，抑制依赖于第一过渡系列元素的金属酶的酶促作用，以及抑制再灌注损伤。